Browse the Peptyds catalogue.

Sermorelin, CJC-1295 and tesamorelin are three different points on the same GHRH map. Only one of them has an EMA EPAR — and that matters more than any forum stack ever will.

Goal-led shopping helps guided buyers compare research context, quality proof, and product fit without decoding every molecule first.

CJC-1295 and ipamorelin are talked about together because they hit two different parts of the growth-hormone axis. The interesting part of the comparison is mechanism, not which one is 'stronger'.

This is the question underneath the entire growth-hormone category, and most comparisons skip it: are you adding the hormone, or asking the body for more of its own?

Three molecules that all touch the GH/IGF-1 axis, three completely different mechanisms, three very different evidence bases. The honest comparison is structural, not which-is-best.

Three GLP-1 family peptides, three different receptor mechanisms, three different regulatory positions in Europe. Here is what the published trials and the EMA EPARs actually say.